Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Cash (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Change in Cash for 15 consecutive years, with $372.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 421.1% year-over-year to $372.8 million, compared with a TTM value of $480.0 million through Dec 2025, up 2751.93%, and an annual FY2025 reading of $480.0 million, up 2751.93% over the prior year.
  • Change in Cash was $372.8 million for Q4 2025 at Neurocrine Biosciences, up from $76.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $372.8 million in Q4 2025 and bottomed at -$256.6 million in Q2 2024.
  • Average Change in Cash over 4 years is $47.4 million, with a median of $69.9 million recorded in 2025.
  • The sharpest move saw Change in Cash tumbled 553.36% in 2024, then surged 421.1% in 2025.
  • Year by year, Change in Cash stood at $165.5 million in 2021, then tumbled by 125.74% to -$42.6 million in 2023, then plummeted by 172.54% to -$116.1 million in 2024, then soared by 421.1% to $372.8 million in 2025.
  • Business Quant data shows Change in Cash for NBIX at $372.8 million in Q4 2025, $76.2 million in Q3 2025, and $69.9 million in Q2 2025.